#Precision medicine

[cbirt]

In a recently published study, Stanford Medicine researchers highlighted age-related problems in humans and showed how aging varies from person to person and between organs within an individual. Researchers used human blood plasma protein levels from particular organs to examine aging in 11 key organs in real people. The approach suggested by the authors offers a straightforward and comprehensible way to research the aging of organs. Understanding the molecular changes in human organs is crucial for addressing the global disease burden and revolutionizing patient care, preventative medicine, and drug development. Current methods present are either expensive or need to provide the required molecular insights. To combat this problem, the researchers hypothesized that complete quantification of organ-specific proteins in plasma could enable minimally invasive assessment and tracking of human aging for any organ.

Continue Reading

#diagnostics #precision medicine #proteomics #bioinformatics #machine learning #health

[eretzyisrael]

Good News From Israel

In the 16th July 23 edition of Israel’s good news, the highlights include:

Israeli personally tailored therapies can cure infections and infertility.

Israeli surgeons don’t need electricity to save a life in Ethiopia.

Israeli scientists won awards from France and NASA.

A new European fund is to invest a quarter of a billion dollars in Israeli startups.

An Israeli startup will generate electricity from Taiwan’s choppy seas.

The Israel Premier Tech cycling team won the 9th stage of the Tour de France.

An Israeli NGO is saving the bees – one swarm at a time.

This newsletter edition is entitled "Chai-Tech", merging the term "Hi-Tech" with "Chai" - the Hebrew word for "Living" / "Lives". The reason is that there is so much recent news about Israeli technology to benefit human lives.

Almost all the medical articles involve Israelis using hi-tech to save lives, including breakthroughs in personalized medicine, global vaccines, stroke monitors, digital  insoles, brain disease diagnosis, prescription checkers and the innovations of Sheba Medical Center.

Israeli life-saving climate-tech features high in this newsletter with Israel's plans for a 1,000-strong delegation to COP28, the recent climate-tech delegation to the UK, 15 Israeli Climate Awards candidates, France's award to an Israeli hydrogen scientist, and Taiwan implementing Israel's wave energy solution.  Israeli hi-tech is also benefiting the environment by using seaweed to generate electricity, turning potato waste foliage into a food source, more vegan substitutes for meat, sustainable farming solutions and ultra-efficient space propulsion.

Other hi-tech programs include multi-million investments into Israeli companies developing 3D printed organs, security for schools, digital health, food-tech and agri-tech solutions. No wonder Israeli hi-tech startups are actively being sought by the US States of Virginia and Maryland.

The photo shows the construction of a solar roof over the soccer pitch of our local school in Netanya, providing shade to the young players, and green electricity for the school and the grid. Another "high"-tech solution making life better for the next generation.  Am Yisrael Chai!

Read More: Good News From Israel

#Arab #climate #COP28 #Ethiopia #food waste #good news #hydrogen #Israel #Jewish #Maryland #precision medicine #Saudi Arabia #STEM #strokes #Taiwan #Tour de France #UAE #vaccine #vegan #Virginia

[gyanconsulting]

The healthcare industry is undergoing a paradigm shift towards value-based, patient-centric care in the era of precision medicine. Patients are increasingly asserting their desire to actively participate and have a significant say in their healthcare decisions. Merely acknowledging patient values as a formality is...

#precision medicine #healthcare innovation #healthcare industry #Digital Transformation #digital healthcare

[innonurse]

#health tech #verily #alphabet #google #big tech #medtech #precision medicine #life sciences

[airises]

"Revolutionizing Biotech: How AI is Transforming the Industry"

The biotech industry is on the cusp of a revolution, and Artificial Intelligence (AI) is leading the charge. AI is transforming the way biotech researchers and developers work, enabling them to make groundbreaking discoveries and develop innovative solutions at an unprecedented pace. “Accelerating Scientific Discovery with AI” AI is augmenting human capabilities in biotech research, enabling…

View On WordPress

#Agricultural Biotech #agriculture #ai #Artificial Intelligence #bioinformatics #Biological Systems #Biomedical Engineering. #Biotech #Data Analysis #Drug Discovery #Environment #genetics #genomics #healthcare #innovation #Machine Learning #personalized medicine #Precision Medicine #Research #science #synthetic biology #technology

[medicomunicare]

Il ruolo degli ormoni sessuali nel controllo e nella responsività biologica dei diversi tipi di tumore mammario

Gli ormoni sessuali sono una parte importante sia della patogenesi che nella progressione del carcinoma mammario. Ognuni di essi ha le sue azioni molecolari sulle cellule tumorali, mediate dalla loro interazione con i recettori nucleari che ahnno funzione di fattori di trascrizione. Regolarmente il carcinoma mammario è molto responsivo agli estrogeni, eccetto la forma triplo-negativa che non…

View On WordPress

#androgeni #aromatasi #biomarkers #carcinoma mammario #cellular signaling #enzalutamide #espressione genica #estradiolo #estrogeni #letrozolo #medicina personalizzata #oncogenesi #precision medicine #progesterone #recettore #replicazione cellulare #triple-negative #tumore al seno

[rashorx]

#Precision Medicine #pharmacogenomics (pgx) testing washington

[gauricmi]

Personalized Approaches to Cutaneous Squamous Cell Carcinoma Treatment: Targeting Tumor Diversity

Cutaneous Squamous Cell Carcinoma (cSCC) is a heterogeneous disease characterized by diverse clinical and molecular features. Personalized treatment approaches that take into account the unique characteristics of individual tumors have emerged as a promising strategy to improve treatment outcomes and patient survival.

Understanding Cutaneous Squamous Cell Carcinoma: Cutaneous Squamous Cell Carcinoma (cSCC) is a type of skin cancer that arises from the malignant transformation of squamous cells in the epidermis or its appendages. It encompasses a spectrum of disease presentations, ranging from localized lesions to metastatic tumors with varying clinical behaviors.

Tumor Heterogeneity and Molecular Subtypes: Cutaneous Squamous Cell Carcinoma (cSCC) exhibits considerable heterogeneity at the molecular level, with distinct genetic alterations and signaling pathways driving tumor progression and metastasis. Molecular subtyping studies have identified different subgroups of cSCC tumors based on their genomic profiles, providing insights into tumor diversity and potential therapeutic targets.

Precision Medicine in cSCC Treatment: Precision medicine approaches aim to tailor treatment strategies to the specific molecular characteristics of individual tumors, allowing for more targeted and effective therapies. By identifying actionable mutations or biomarkers, clinicians can select therapies that are most likely to benefit patients while minimizing the risk of treatment-related toxicities.

Genomic Profiling and Biomarker Identification: Advances in genomic sequencing technologies have enabled comprehensive profiling of cSCC tumors, revealing recurrent mutations in genes involved in cell cycle regulation, DNA repair, and immune evasion. Biomarker identification efforts seek to identify predictive markers of treatment response and prognosis, guiding treatment decisions in personalized medicine.

Get More Insights On This Topic: Cutaneous Squamous Cell Carcinoma

#Cutaneous Squamous Cell Carcinoma #Skin Cancer #Tumor Heterogeneity #Precision Medicine #Molecular Subtypes #Targeted Therapy #Immunotherapy #Biomarker Identification #Personalized Treatment

[techninja]

Precision and Innovation: Image-Guided Radiation Therapy Reshaping Cancer Treatment

Image-Guided Radiation Therapy (IGRT) is reshaping the landscape of cancer treatment, offering a precise and innovative approach to targeting tumors while minimizing damage to surrounding healthy tissues. By combining advanced imaging techniques with targeted radiation delivery, IGRT enables oncologists to visualize the tumor in real-time and adapt treatment parameters for optimal results. This personalized approach to cancer care has led to improved clinical outcomes, reduced side effects, and enhanced quality of life for patients undergoing radiation therapy.

One of the key advantages of IGRT is its ability to account for anatomical changes and patient motion throughout the course of treatment. By incorporating imaging data into treatment planning and delivery processes, IGRT ensures precise radiation delivery while minimizing the risk of underdosing the tumor or irradiating healthy tissues. This real-time monitoring and adjustment of treatment parameters enhance treatment accuracy and safety, particularly for tumors located in complex or sensitive areas of the body.

Moreover, the integration of IGRT with other advanced radiation therapy techniques, such as intensity-modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT), further enhances treatment precision and effectiveness. Combined with computerized treatment planning systems and image registration algorithms, IGRT enables oncologists to optimize treatment plans and tailor therapy to each patient's unique anatomy and tumor characteristics. This personalized approach maximizes therapeutic benefit while minimizing the risk of complications, offering new hope to patients facing a cancer diagnosis.

The adoption of IGRT is on the rise worldwide, driven by the increasing prevalence of cancer and the growing demand for advanced treatment modalities. As healthcare providers prioritize value-based care and patient-centered approaches, IGRT stands out as a transformative technology that aligns with these objectives by delivering targeted, precise, and efficient cancer treatment. Moreover, ongoing research and development efforts aimed at enhancing IGRT technologies and workflows are expected to further drive innovation and expand the applications of this cutting-edge therapy in oncology.

In conclusion, Image-Guided Radiation Therapy represents a significant advancement in cancer treatment, offering patients a more precise, effective, and personalized approach to radiation therapy. With its ability to visualize tumors in real-time and adapt treatment parameters accordingly, IGRT has become an indispensable tool in the fight against cancer. As technology continues to evolve and healthcare providers embrace innovative treatment modalities, IGRT is poised to play a central role in shaping the future of cancer care.

#cancer treatment #precision medicine #oncology #radiation therapy #medical imaging #tumor targeting #personalized healthcare #treatment innovation

[jcmarketresearch]

#precision medicine #precision medicine market #global precision medicine market #precision medicine market size #Jasper Colin

[pharmanucleus1]

Antimicrobial Susceptibility Market: Precision in Pathogen Control

Antimicrobial Susceptibility Testing Market

The worldwide antimicrobial susceptibility testing market is expected to increase at a 5.5% CAGR from 2022 to 2027, from an anticipated value of US$3.6 billion in 2022 to US$4.7 billion in 2027. The Antimicrobial Susceptibility Testing (AST) Technology Market is expanding due to factors such as rising infectious illness prevalence, increased antibiotic resistance, and favourable government measures to minimise infectious disease burden. Antibiotic susceptibility testing is becoming more popular due to the rising prevalence of certain illnesses, such as bloodstream infections and pneumonia caused by E. coli, K. pneumonia, and P. aeruginosa, among others.

Click here for full report:

https://www.pharmanucleus.com/reports/antimicrobial-susceptibility-market

Antimicrobial Susceptibility Testing Market Dynamics

Drivers: Emergence of multidrug resistance due to drug abuse

The rise of drug resistance poses a significant threat to global health, particularly in the context of antibiotics. Antibiotics are becoming less effective as drug-resistant strains of bacteria spread worldwide. This has profound implications for disease treatment, as it makes infections more difficult to treat and ultimately increases mortality rates.

The World Health Organization (WHO) has identified drug-resistant pathogens, such as carbapenem-resistant gram-negative bacteria, as a major concern. Urgent development of new drugs is necessary to combat these infections effectively. However, without a fundamental change in the way antibiotics are used, the effectiveness of these new treatments may be compromised.

Misuse and overuse of antibiotics contribute to the development of drug resistance. Factors such as inappropriate prescribing, improper self-medication, and the use of antibiotics in livestock and agriculture all contribute to the problem. These practices create an environment where bacteria can adapt and develop resistance mechanisms, rendering antibiotics less effective over time.

To preserve the efficacy of antibiotics, it is crucial to promote responsible antibiotic use. This includes raising awareness among healthcare providers and the general public about appropriate antibiotic prescribing and the importance of completing prescribed courses of treatment. Additionally, robust regulations and surveillance systems are needed to monitor antibiotic use in various sectors, including healthcare, agriculture, and veterinary medicine.

Efforts to develop new antibiotics should be complemented by strategies to optimize their use, such as antibiotic stewardship programs and infection prevention and control measures. Research into alternative treatment options, such as phage therapy and immunotherapies, is also essential to diversify the arsenal against drug-resistant bacteria.

Opportunities: Growth opportunities in emerging market

The antimicrobial susceptibility testing market players are poised with significant opportunities in developing countries such as APAC (Asia-Pacific), India, China, and Japan. These countries are experiencing a notable growth in the antimicrobial susceptibility testing market, driven by several factors.

Firstly, the booming medical tourism industry in these regions attracts a large influx of patients seeking healthcare services, including diagnostics. This surge in medical tourism creates a demand for antimicrobial susceptibility testing as part of the diagnostic process.

Secondly, the adult population (over 20 years old) is growing in these countries, leading to a higher prevalence of infectious diseases. As a result, there is an increased need for accurate and timely antimicrobial susceptibility testing to guide appropriate treatment decisions.

Additionally, the increasing use of drugs in these regions contributes to the demand for antimicrobial susceptibility testing. With a growing population and expanding healthcare access, the requirement for testing to guide optimal drug selection and treatment outcomes becomes crucial.

Moreover, these countries possess a strong and skilled workforce that is well-versed in high technology. This skilled workforce plays a vital role in the successful implementation and operation of advanced antimicrobial susceptibility testing technologies, ensuring accurate and reliable results.

Furthermore, the relatively lax import/export laws in these regions provide an advantageous environment for market players to expand their brands and offerings. The underdeveloped nature of certain areas in these countries presents opportunities for companies to introduce and establish their technologies, filling gaps in the market and addressing unmet needs. 

The growing number of technicians and their desire to learn and adopt new technologies further contribute to the development and updating of antimicrobial susceptibility testing capabilities in these regions, fostering innovation and advancements in the field.

Click here for full report:

https://www.pharmanucleus.com/reports/antimicrobial-susceptibility-market

Challenges: Complex Regulatory Frameworks

One of the major challenges in antibiotic susceptibility testing is the time gap between establishing clinical thresholds, obtaining regulatory approval for innovative antimicrobial treatments, and bringing those drugs to market. The process of gaining approval for new drugs involves stringent guidelines set by regulatory bodies like the FDA, which can result in significant delays.

The lack of established clinical thresholds for certain drugs further complicates the use of products aimed at increasing the susceptibility of microorganisms. Clinical thresholds are important benchmarks used to determine the effectiveness and appropriate usage of antimicrobial therapies. In some cases, such as invasive mold infections other than Aspergillus, the efficacy of antifungal therapy cannot be accurately assessed without the availability of specific clinical thresholds.

This time lag and absence of clinical thresholds can hinder the timely utilization of innovative antimicrobial treatments. It delays access to potentially life-saving therapies and limits healthcare professionals' ability to make informed decisions regarding treatment choices. The gap between setting clinical thresholds, regulatory approval, and market availability needs to be addressed to ensure that effective antimicrobial treatments reach patients in a timely manner and contribute to the fight against drug-resistant microorganisms.

Click here for request free sample:

https://www.pharmanucleus.com/request-sample/1193

Restraints: High Cost of automated Laboratory Instruments

Automated equipment for antimicrobial laboratories is quite expensive and offers premium features and functionality. The introduction of automated AST systems shortens incubation and detection times. Another barrier to this market is the high maintenance cost of  these devices, which come with the latest software and require regular maintenance.

#antimicrobial susceptibility #pathogen control #infection management #precision medicine #microbial resistance solutions

[cbirt]

Advances in high-throughput omics profiling have improved cancer patient classification significantly. However, insufficient data in multi-omics integration is a big problem because conventional techniques like imputation and sample exclusion frequently jeopardize biological connections and diversity. Moreover, it is sometimes overlooked how important it is to appropriately classify newly diagnosed patients with incomplete omics data into preexisting categories. Researchers from the University of Toronto, Canada, and their collaborators present IntegrAO (Integrate Any Omics), an unsupervised framework for integrating insufficient multi-omics data and categorizing novel samples. To create unified patient embeddings, IntegrAO first merges partially overlapping patient graphs from several omics sources and applies graph neural networks.

Our genetic landscape is now painted in great depth by high-throughput omics technologies like transcriptomics and genomics, which provide previously unheard-of insights into health and disease. These technologies power patient stratification in the field of cancer, an essential procedure that divides patients into groups according to their distinct biological profiles. This, in turn, opens the door for precision oncology, in which individualized therapy regimens are designed for each patient. The road to customized treatment is rarely easy. A significant obstacle is the intrinsic incompleteness of omics data. Precision medicine and illness subtyping have made progress, but they are all limited by the need for comprehensive data across samples. This requirement becomes troublesome since missing data in profile assays is common, frequently the result of budgetary or experimental limitations.

Continue Reading

#bioinformatics #cancer #neural network #precision medicine

[pathologylab]

📢Exciting Announcement! Join us for an insightful talk by our Founder and CEO, Neeraj Gupta, at the upcoming VOICE OF HEALTHCARE (VOH) and Next Edge Precision Med India Conclave & Awards 2024!

Get ready to be inspired as Mr. Neeraj Gupta will be sharing his invaluable insights and expertise in the realm of healthcare innovation and precision medicine. Don't miss out on this exceptional opportunity to learn about G2M's groundbreaking contributions to the healthcare industry with its innovative NGS, POC, RT-PCR, and Extraction solutions!

Save the date and mark your calendars! See you there!

🗓 March 31, 2024

📍 Le Meridien Hotel, New Delhi

𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗵𝗲𝗿𝗲: https://app.glueup.com/event/93445/register

NextEdge- Precision Medicine Insights

#VOHConclave2024 #PrecisionMedicine #HealthcareInnovation #Genes2Me #NextEdgePrecisonMed #HealthcareLeadership #PMI2024 #Genomics #Conclave #Partner #G2M

#healthcare innovation #voh conclave 2024 #precision medicine #g2m #genes2me #partner #next edge precison med #pmi 2024 #genomics

[sciencedayforpeaceanddev]

Multi-disciplinary panels to discuss research that advances Toward Science Without Walls.

AAAS is committed to making the Annual Meeting an inclusive space for sharing ideas and knowledge. See our meeting policies and help us foster a safe space for all.  Follow the conversations with the hastags #AAASmtg

2024 AAAS Annual Meeting takes place in Denver, CO, February 15-17. Plenary sessions and Sci-Mic Stage Chats will be streamed live. See schedule and tune in!

Annual Meeting program

Scientific Sessions: Science and technology experts assemble in small multi-disciplinary panels to discuss research that advances Toward Science Without Walls. During these 60-minute sessions, a panel of three speakers give 10-minute presentations followed by audience questions and comments. Lightning Talks: Early career researchers take the stage for ten minutes to discuss their STEM work. Workshops: Workshops are aimed at individuals seeking careers in science and engineering. Workshops are instructional and interactive in nature and are markedly different from a scientific session. Workshops may have up to 3 presenters and will be 60 minutes in length.

SCIENTIFIC SESSION, WORKSHOP, AND LIGHTNING TALK TIMELINE

March 5; 2024 theme is announced, and session submission site opens. May 4; Deadline to propose Scientific Sessions, Workshop, and Lighting Talks. May 15; Session proposal review begins with volunteer session reviewers. July; Program Committee meets for the final review to select Scientific Sessions, Workshop, and Lighting Talks. Mid-August; Scientific Session and Lightning Talk organizers receive accept/decline notifications. Mid-August; Workshop coordinators receive accept/decline notifications. Mid-October; 2023 Annual Meeting program and registration available online. February 16-17; Scientific Sessions, Workshop, and Lighting Talks take place at the 2024 AAAS Annual Meeting.

The session and workshop timeline is updated as of September 13, 2023.

#science and technology #scientific research #precision medicine #scientists #medical sciences #annual meeting #aaas #Scientific Sessions #Workshop #lighting talks #Science Without Walls #workshops #multi-disciplinary panels

[market-insider]

Clinical Trials : Holistic Exploration of the Current State and Future Outlook

The global clinical trials market size is expected to reach USD 123.5 billion by 2030, expanding at a CAGR of 6.49 from 2024 to 2030, according to a new report by Grand View Research, Inc. An increase in the volume and complexity of clinical trials has been witnessed lately, which plays an important role in the R&D of new drugs and products. The market witnessed a decline of 6% in 2020 owing to the COVID-19 pandemic. However, the market is projected to recover from 2021 onwards. In addition, clinical trials have become increasingly costly, adding to the overall cost of developing a drug.

Clinical Trials Market Report Highlights

The phase III clinical trials segment dominated the market with a 53.3% share in 2023. This can be attributed to the complexity of this phase

The interventional studies segment dominated the market in 2023. It is one of the most prominent methods used in clinical trials in the study design segment owing to the increasing demand for the intervention for clinical trials by researchers

North America held 50.3% of the market share in 2023. Favorable government initiatives and the presence of a large number of players in the U.S. that offer advanced services are responsible for market growth

Asia Pacific region is anticipated to grow at the fastest CAGR over the forecast period owing to the increasing patient pool and cost-efficient services.

For More Details or Sample Copy please visit link @: Clinical Trials Market Report

The increasing need for developing new drugs for chronic diseases, such as cancer, respiratory disorders, diabetes, cardiovascular diseases, and others, is creating immense pressure on the healthcare industry. The COVID-19 pandemic and the increasing demand for developing a suitable treatment are driving the market. The high number of people affected by the disease further depicts an increasing need for therapeutics & vaccines. Currently, there are 288 therapeutics and 106 vaccines under development, out of which, nearly 7.0% of therapeutics are in Phase IV, 21.0% in Phase III, and 43.0% & 13.0% in Phase II & Phase I, respectively.

The pandemic has resulted in the global disruption of traditional onsite clinical trials. Hence, regulatory bodies worldwide have undertaken various initiatives for fast-tracking clinical trials for the development of innovative solutions. One such instance is Solidarity, an international clinical trial launched by the WHO to find effective treatment against COVID-19. Although the pandemic has forced many medical device & drug developers to revise the approach to such crises, integrating best practices within clinical trial procedures & adapting to virtual trials, which can support the continuous development of therapeutics.

ClinicalTrials #HealthcareResearch #MedicalInnovation #DrugDevelopment #PatientRecruitment #Biopharmaceuticals #ClinicalResearch #RegulatoryCompliance #DataManagement #PatientEngagement #PrecisionMedicine #TherapeuticTrials #CROs #ClinicalResearchOrganizations #GlobalHealth #ClinicalStudyDesign #PharmaceuticalIndustry #BiotechResearch #ClinicalEndpoints #HealthTechIntegration

#Clinical Trials #Healthcare Research #Medical Innovation #Drug Development #Patient Recruitment #Biopharmaceuticals #Clinical Research #Regulatory Compliance #Data Management #Patient Engagement #Precision Medicine #Therapeutic Trials #CROs #Clinical Research Organizations #Global Health #Clinical Study Design #Pharmaceutical Industry #Biotech Research #Clinical End-points #HealthTech Integration

[healthcareporium]

Precision Medicine Unleashed: The Impact of Gene Therapies on Neuromuscular Health

In the realm of medical breakthroughs, nucleic acid and gene therapies are emerging as promising avenues for revolutionizing the treatment landscape of neuromuscular disorders. From approved therapies to groundbreaking advancements in the pipeline, the trajectory of treating conditions like Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA) is witnessing a transformative…

View On WordPress

#CRISPR-Cas9 #Duchenne Muscular Dystrophy #Gene Therapies #Gene Therapy #Neuromuscular Disorders #Neuromuscular Disorders Treatment #Nucleic Acids #Nucleic Acids And Gene Therapies In Neuromuscular Disorders #Precision Medicine #Spinal Muscular Atrophy